<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">genort</journal-id><journal-title-group><journal-title xml:lang="ru">Гений ортопедии</journal-title><trans-title-group xml:lang="en"><trans-title>Genij Ortopedii</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1028-4427</issn><issn pub-type="epub">2542-131X</issn><publisher><publisher-name>ЦЕНТР ИЛИЗАРОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18019/1028-4427-2026-32-4-479-487</article-id><article-id custom-type="elpub" pub-id-type="custom">genort-3525</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Влияние глюкозамина-хондроитина, хитозана и фитоэстрогенов на воспалительные процессы, биомаркеры дегенерации хряща и клинические симптомы при остеоартрозе коленного сустава у женщин в постменопаузе</article-title><trans-title-group xml:lang="en"><trans-title>Effects of Glucosamine-Chondroitin, Chitosan, and Phytoestrogen on Knee Osteoarthritis Inflammatory and Cartilage Degeneration Biomarkers and Clinical Symptoms in Postmenopausal Women</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Kermawan</surname><given-names>P.</given-names></name><name name-style="western" xml:lang="en"><surname>Kermawan</surname><given-names>P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Yasa</surname><given-names>I.W.P.S.</given-names></name><name name-style="western" xml:lang="en"><surname>Yasa</surname><given-names>I.W.P.S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Karna</surname><given-names>М. B.</given-names></name><name name-style="western" xml:lang="en"><surname>Karna</surname><given-names>M. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Herawati</surname><given-names>S.</given-names></name><name name-style="western" xml:lang="en"><surname>Herawati</surname><given-names>S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Suyasa</surname><given-names>I. K.</given-names></name><name name-style="western" xml:lang="en"><surname>Suyasa</surname><given-names>I. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Arsani</surname><given-names>N.L.K.A.</given-names></name><name name-style="western" xml:lang="en"><surname>Arsani</surname><given-names>N.L.K.A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Calisto</surname><given-names>K. E.</given-names></name><name name-style="western" xml:lang="en"><surname>Calisto</surname><given-names>K. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Yogyakarta</p></bio><bio xml:lang="en"><p>Yogyakarta</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Yogananda</surname><given-names>K.S.S.</given-names></name><name name-style="western" xml:lang="en"><surname>Yogananda</surname><given-names>K.S.S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Yogyakarta</p></bio><bio xml:lang="en"><p>Yogyakarta</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Wiwekananda</surname><given-names>K.S.S.</given-names></name><name name-style="western" xml:lang="en"><surname>Wiwekananda</surname><given-names>K.S.S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Yogyakarta</p></bio><bio xml:lang="en"><p>Yogyakarta</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Wijaya</surname><given-names>N.S.N.</given-names></name><name name-style="western" xml:lang="en"><surname>Wijaya</surname><given-names>N.S.N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Jawi</surname><given-names>I. M.</given-names></name><name name-style="western" xml:lang="en"><surname>Jawi</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Bali</p></bio><bio xml:lang="en"><p>Bali</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Universitas Pendidikan Ganesha</institution><country>Индонезия</country></aff><aff xml:lang="en"><institution>Universitas Pendidikan Ganesha</institution><country>Indonesia</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Udayana University</institution><country>Индонезия</country></aff><aff xml:lang="en"><institution>Udayana University</institution><country>Indonesia</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Ngoerah General Hospital, Udayana University</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ngoerah General Hospital, Udayana University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Universitas Gadjah Mada</institution><country>Индонезия</country></aff><aff xml:lang="en"><institution>Universitas Gadjah Mada</institution><country>Indonesia</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>18</day><month>08</month><year>2026</year></pub-date><volume>32</volume><issue>4</issue><fpage>479</fpage><lpage>487</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kermawan P., Yasa I., Karna М.B., Herawati S., Suyasa I.K., Arsani N., Calisto K.E., Yogananda K., Wiwekananda K., Wijaya N., Jawi I.M., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Kermawan P., Yasa I., Karna М.B., Herawati S., Suyasa I.K., Arsani N., Calisto K.E., Yogananda K., Wiwekananda K., Wijaya N., Jawi I.M.</copyright-holder><copyright-holder xml:lang="en">Kermawan P., Yasa I., Karna M.B., Herawati S., Suyasa I.K., Arsani N., Calisto K.E., Yogananda K., Wiwekananda K., Wijaya N., Jawi I.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ilizarov-journal.com/jour/article/view/3525">https://www.ilizarov-journal.com/jour/article/view/3525</self-uri><abstract><sec><title>Введение</title><p>Введение. Остеоартроз коленного сустава (ОА) — прогрессирующее заболевание, вызывающее боль и дисфункцию коленного сустава, особенно у женщин в постменопаузе.</p><p>Цель работы — оценить терапевтическую эффективность комбинации глюкозамина-хондроитина, хитозана, фитоэстрогена и парацетамола по сравнению с применением только парацетамола у женщин в постменопаузе с остеоартрозом коленного сустава.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведено двойное слепое рандомизированное контролируемое исследование с участием 60 женщин в постменопаузе с остеоартрозом коленного сустава II–III степени по Келлгрену – Лоуренсу, которые случайным образом распределены на две группы: основную (n = 30) — пациентки получали глюкозамин-хондроитин, хитозан и фитоэстроген в сочетании с парацетамолом, и контрольную группу (n = 30) — пациентки получали только парацетамол. Возраст пациенток основной группы — (59,77 ± 2,99) г., контрольной группы — (60,4 ± 3,21) г., статистически значимых различий не выявлено (p = 0,43). Уровни растворимого рецептора интерлейкина-6 (sIL-6R), интерлейкина-10 (IL-10), олигомерного матриксного белка хряща (COMP), а также показатели визуальной аналоговой шкалы (ВАШ) и индекса остеоартрита по системе Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) измеряли до лечения и после двух недель лечения.</p></sec><sec><title>Результаты</title><p>Результаты. После фармакологического вмешательства в основной группе наблюдали значимое снижение показателей WOMAC, COMP и sIL-6R по сравнению с контрольной группой (p &lt; 0,01). В обеих группах после лечения зарегистрировано повышение уровня IL-10, более выраженное в контрольной группе.</p></sec><sec><title>Обсуждение</title><p>Обсуждение. Комбинированная терапия продемонстрировала улучшение показателей функции сустава и снижение маркеров воспаления и дегенерации хряща. Эти данные подтверждают противовоспалительный и хондропротективный потенциал природных соединений в лечении пациентов с остеоартрозом коленного сустава.</p></sec><sec><title>Заключение</title><p>Заключение. Использование комбинации глюкозамин-хондроитина, хитозана, фитоэстрогена и парацетамола у женщин в постменопаузе с остеоартритом коленного сустава II–III степени продемонстрировало лучшие краткосрочные результаты снижения показателей биомаркеров воспаления и дегенерации хряща, а также улучшение клинических симптомов по сравнению с использованием одного парацетамола.</p></sec></abstract><trans-abstract xml:lang="en"><p>Introduction Knee osteoarthritis (OA) is a progressive disease causing pain and dysfunction in postmenopausal women.</p><p>Purpose This study aimed to evaluate the therapeutic efficacy of a combination of glucosamine-chondroitin, chitosan, and phytoestrogen with paracetamol compared to paracetamol alone in postmenopausal women with knee osteoarthritis.</p><p>Materials and Methods A double-blind randomized controlled trial was conducted on 60 postmenopausal women with Kellgren – Lawrence grade II–III knee osteoarthritis. A total of 60 patients were included in this study and divided into treatment and control groups with a 1:1 ratio. The mean age of patients was 59.77 years (± 2.99) while the control group had a mean age of 60.4 years (± 3.21), there was no significant difference (p = 0.43). Patients were randomly assigned into two groups: the treatment group (n = 30), which received glucosamine-chondroitin, chitosan, and phytoestrogen in combination with paracetamol, and the control group (n = 30), which received paracetamol alone. The levels of soluble interleukin-6 receptor (sIL-6R), interleukin-10 (IL-10), cartilage oligomeric matrix protein (COMP), as well as Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were measured at baseline and after two weeks of treatment.</p><p>Results After the pharmacological intervention, the treatment group showed significant reductions in WOMAC score, COMP, and sIL-6R compared to the control group (p &lt; 0.01). Both groups had increased IL-10 levels following treatment, but the increase was greater in the control group.</p><p>Discussion The combination therapy demonstrated improvement in joint function and a reduction in inflammatory and cartilage degeneration markers. These findings support the anti-inflammatory and chondroprotective potential of natural compounds in the management of knee osteoarthritis.</p><p>Conclusion The combination of glucosamine-chondroitin, chitosan, phytoestrogen, and paracetamol demonstrated superior short-term effects in reducing inflammatory and cartilage degeneration biomarkers and improving clinical symptoms in postmenopausal women with grade II-III knee osteoarthritis compared with paracetamol alone.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартроз коленного сустава</kwd><kwd>постменопауза</kwd><kwd>глюкозамин-хондроитин</kwd><kwd>хитозан</kwd><kwd>фитоэстроген</kwd></kwd-group><kwd-group xml:lang="en"><kwd>knee osteoarthritis</kwd><kwd>postmenopausa</kwd><kwd>glucosamine-chondroitin</kwd><kwd>chitosan</kwd><kwd>phytoestrogen</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы выражают искреннюю благодарность всем пациентам, любезно принявшим участие в данном исследовании. Мы также выражаем благодарность Фанди Хендравану за его ценный вклад в анализ данных</funding-statement><funding-statement xml:lang="en">The authors sincerely thank all the patients who participated in this study. We also acknowledge Fandi Hendrawan for his valuable contribution to data analysis</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Osteoarthritis. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/osteoarthritis. Accessed Sept 19, 2025.</mixed-citation><mixed-citation xml:lang="en">WHO. Osteoarthritis. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/osteoarthritis. Accessed Sept 19, 2025.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Menopause. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/menopause. Accessed Sept 19, 2025.</mixed-citation><mixed-citation xml:lang="en">WHO. Menopause. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/menopause. Accessed Sept 19, 2025.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Primorac D, Molnar V, Matišić V, et al. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies' Guidelines. Pharmaceuticals (Basel). 2021;14(3):205. doi: 10.3390/ph14030205.</mixed-citation><mixed-citation xml:lang="en">Primorac D, Molnar V, Matišić V, et al. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies' Guidelines. Pharmaceuticals (Basel). 2021;14(3):205. doi: 10.3390/ph14030205.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu H, Siwiec RM. Knee Osteoarthritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publ.; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507884/. Accessed Sept 19, 2025.</mixed-citation><mixed-citation xml:lang="en">Hsu H, Siwiec RM. Knee Osteoarthritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publ.; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507884/. Accessed Sept 19, 2025.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Arellano RD, Aguilar LS, Argüello R, et al. Cartilage Oligomeric Matrix Protein Levels in Synovial Fluid in Patients With Primary Knee Osteoarthritis And Healthy Controls: A Preliminary Comparative Analysis With Serum Cartilage Oligomeric Matrix Protein. Arch Rheumatol. 2017;32(3):189-196. doi: 10.5606/ArchRheumatol.2017.6220.</mixed-citation><mixed-citation xml:lang="en">Arellano RD, Aguilar LS, Argüello R, et al. Cartilage Oligomeric Matrix Protein Levels in Synovial Fluid in Patients With Primary Knee Osteoarthritis And Healthy Controls: A Preliminary Comparative Analysis With Serum Cartilage Oligomeric Matrix Protein. Arch Rheumatol. 2017;32(3):189-196. doi: 10.5606/ArchRheumatol.2017.6220.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63(9):1028-1034. doi: 10.1136/ard.2003.011403.</mixed-citation><mixed-citation xml:lang="en">Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63(9):1028-1034. doi: 10.1136/ard.2003.011403.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kermawan P, Karna MB, Jawi IM, et al. Potential use of glucosamine, chondroitine, chitosan and phytoestrogen for patients with osteoarthritis. Int J Res Med Sci. 2022;10(10):2316-2319. doi: 10.18203/2320-6012.ijrms20222543.</mixed-citation><mixed-citation xml:lang="en">Kermawan P, Karna MB, Jawi IM, et al. Potential use of glucosamine, chondroitine, chitosan and phytoestrogen for patients with osteoarthritis. Int J Res Med Sci. 2022;10(10):2316-2319. doi: 10.18203/2320-6012.ijrms20222543.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bannwarth B, Péhourcq F. Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs. 2003;63 Spec No 2:5-13. (In French)</mixed-citation><mixed-citation xml:lang="en">Bannwarth B, Péhourcq F. Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs. 2003;63 Spec No 2:5-13. (In French)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kirkham SG, Samarasinghe RK. Review article: Glucosamine. J Orthop Surg (Hong Kong). 2009;17(1):72-76. doi: 10.1177/230949900901700116.</mixed-citation><mixed-citation xml:lang="en">Kirkham SG, Samarasinghe RK. Review article: Glucosamine. J Orthop Surg (Hong Kong). 2009;17(1):72-76. doi: 10.1177/230949900901700116.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Oprenyeszk F, Chausson M, Maquet V, et al. Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit: a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in an hydrogel. Osteoarthritis Cartilage. 2013;21(8):1099-1107. doi: 10.1016/j.joca.2013.04.017.</mixed-citation><mixed-citation xml:lang="en">Oprenyeszk F, Chausson M, Maquet V, et al. Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit: a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in an hydrogel. Osteoarthritis Cartilage. 2013;21(8):1099-1107. doi: 10.1016/j.joca.2013.04.017.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121-126. doi: 10.4103/0253-7176.116232.</mixed-citation><mixed-citation xml:lang="en">Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121-126. doi: 10.4103/0253-7176.116232.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lubis AMT, Siagian C, WonggokusumaE, etal. Comparison of Glucosamine-Chondroitin Sulfatewith and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Acta Med Indones. 2017;49(2):105-111.</mixed-citation><mixed-citation xml:lang="en">Lubis AMT, Siagian C, WonggokusumaE, etal. Comparison of Glucosamine-Chondroitin Sulfatewith and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Acta Med Indones. 2017;49(2):105-111.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kantor ED, Lampe JW, Navarro SL, et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014;20(6):479-485. doi: 10.1089/acm.2013.0323.</mixed-citation><mixed-citation xml:lang="en">Kantor ED, Lampe JW, Navarro SL, et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014;20(6):479-485. doi: 10.1089/acm.2013.0323.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lecomte S, Demay F, Ferrière F, Pakdel F. Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects? Int J Mol Sci. 2017;18(7):1381. doi: 10.3390/ijms18071381.</mixed-citation><mixed-citation xml:lang="en">Lecomte S, Demay F, Ferrière F, Pakdel F. Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects? Int J Mol Sci. 2017;18(7):1381. doi: 10.3390/ijms18071381.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tu J, Xu Y, Xu J, Ling Y, Cai Y. Chitosan nanoparticles reduce LPS-induced inflammatory reaction via inhibition of NF-B pathway in Caco-2 cells. Int J Biol Macromol. 2016;86:848-856. doi: 10.1016/j.ijbiomac.2016.02.015.</mixed-citation><mixed-citation xml:lang="en">Tu J, Xu Y, Xu J, Ling Y, Cai Y. Chitosan nanoparticles reduce LPS-induced inflammatory reaction via inhibition of NF-B pathway in Caco-2 cells. Int J Biol Macromol. 2016;86:848-856. doi: 10.1016/j.ijbiomac.2016.02.015.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chavda VP, Chaudhari AZ, Balar PC, et al. Phytoestrogens: Chemistry, potential health benefits, and their medicinal importance. Phytother Res. 2024;38(6):3060-3079. doi: 10.1002/ptr.8196.</mixed-citation><mixed-citation xml:lang="en">Chavda VP, Chaudhari AZ, Balar PC, et al. Phytoestrogens: Chemistry, potential health benefits, and their medicinal importance. Phytother Res. 2024;38(6):3060-3079. doi: 10.1002/ptr.8196.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of Osteoarthritis with Avocado/Soybean Unsaponifiables. Cartilage. 2015;6(1):30-44. doi: 10.1177/1947603514554992.</mixed-citation><mixed-citation xml:lang="en">Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of Osteoarthritis with Avocado/Soybean Unsaponifiables. Cartilage. 2015;6(1):30-44. doi: 10.1177/1947603514554992.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dresler S, Wójciak-Kosior M, Sowa I, et al. Effect of Long-Term Strontium Exposure on the Content of Phytoestrogens and Allantoin in Soybean. Int J Mol Sci. 2018;19(12):3864. doi: 10.3390/ijms19123864.</mixed-citation><mixed-citation xml:lang="en">Dresler S, Wójciak-Kosior M, Sowa I, et al. Effect of Long-Term Strontium Exposure on the Content of Phytoestrogens and Allantoin in Soybean. Int J Mol Sci. 2018;19(12):3864. doi: 10.3390/ijms19123864.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771-5777. doi: 10.4049/jimmunol.180.9.5771.</mixed-citation><mixed-citation xml:lang="en">Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771-5777. doi: 10.4049/jimmunol.180.9.5771.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang GX, Yu S, Gran B, Rostami A. Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response. J Immunol. 2005;175(11):7202-7208. doi: 10.4049/jimmunol.175.11.7202.</mixed-citation><mixed-citation xml:lang="en">Zhang GX, Yu S, Gran B, Rostami A. Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response. J Immunol. 2005;175(11):7202-7208. doi: 10.4049/jimmunol.175.11.7202.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kong Y, Zhang Y, Zhao X, et al. Carboxymethyl-chitosan attenuates inducible nitric oxide synthase and promotes interleukin-10 production in rat chondrocytes. Exp Ther Med. 2017;14(6):5641-5646. doi: 10.3892/etm.2017.5258.</mixed-citation><mixed-citation xml:lang="en">Kong Y, Zhang Y, Zhao X, et al. Carboxymethyl-chitosan attenuates inducible nitric oxide synthase and promotes interleukin-10 production in rat chondrocytes. Exp Ther Med. 2017;14(6):5641-5646. doi: 10.3892/etm.2017.5258.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Minshawi F, Lanvermann S, McKenzie E, et al. The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. Front Immunol. 2020;11:1794. doi: 10.3389/fimmu.2020.01794.</mixed-citation><mixed-citation xml:lang="en">Minshawi F, Lanvermann S, McKenzie E, et al. The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. Front Immunol. 2020;11:1794. doi: 10.3389/fimmu.2020.01794.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bhadricha H, Patel V, Singh AK, et al. Increased frequency of Th17 cells and IL-17 levels are associated with low bone mineral density in postmenopausal women. Sci Rep. 2021;11(1):16155. doi: 10.1038/s41598-021-95640-0.</mixed-citation><mixed-citation xml:lang="en">Bhadricha H, Patel V, Singh AK, et al. Increased frequency of Th17 cells and IL-17 levels are associated with low bone mineral density in postmenopausal women. Sci Rep. 2021;11(1):16155. doi: 10.1038/s41598-021-95640-0.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Singh B, Kumari S, Kureel AK, et al. In-vitro evidence indicating that IL-10 causes aging-related hypoalbuminemia via JAK1/STAT3 and CEBP-β. Exp Cell Res. 2024;443(1):114327. doi: 10.1016/j.yexcr.2024.114327.</mixed-citation><mixed-citation xml:lang="en">Singh B, Kumari S, Kureel AK, et al. In-vitro evidence indicating that IL-10 causes aging-related hypoalbuminemia via JAK1/STAT3 and CEBP-β. Exp Cell Res. 2024;443(1):114327. doi: 10.1016/j.yexcr.2024.114327.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Suyasa IK, Kawiyana IK, Bakta IM, Widiana IG. Interleukin-6 and ratio of plasma interleukin-6/interleukin-10 as risk factors of symptomatic lumbar osteoarthritis. World J Orthop. 2017;8(2):149-155. doi: 10.5312/wjo.v8.i2.149.</mixed-citation><mixed-citation xml:lang="en">Suyasa IK, Kawiyana IK, Bakta IM, Widiana IG. Interleukin-6 and ratio of plasma interleukin-6/interleukin-10 as risk factors of symptomatic lumbar osteoarthritis. World J Orthop. 2017;8(2):149-155. doi: 10.5312/wjo.v8.i2.149.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hadeel A. Hameed, Hassan AF. The Prophylactic Anti-Inflammatory Effect of Omega-7 Against Paracetamol-Induced Liver Injury in Rats. Iraqi J Vet Med. 2022;46(2):43-47. doi: 0000-0001-8089-4726.</mixed-citation><mixed-citation xml:lang="en">Hadeel A. Hameed, Hassan AF. The Prophylactic Anti-Inflammatory Effect of Omega-7 Against Paracetamol-Induced Liver Injury in Rats. Iraqi J Vet Med. 2022;46(2):43-47. doi: 0000-0001-8089-4726.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tseng S, Reddi AH, Di Cesare PE. Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis. Biomark Insights. 2009;4:33-44. doi: 10.4137/bmi.s645.</mixed-citation><mixed-citation xml:lang="en">Tseng S, Reddi AH, Di Cesare PE. Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis. Biomark Insights. 2009;4:33-44. doi: 10.4137/bmi.s645.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fan X, Chen G, Wang S, et al. Applications of Chitosan and its Derivatives in the Treatment of Osteoarthritis. Aging Dis. 2024. doi: 10.14336/AD.2024.1080.</mixed-citation><mixed-citation xml:lang="en">Fan X, Chen G, Wang S, et al. Applications of Chitosan and its Derivatives in the Treatment of Osteoarthritis. Aging Dis. 2024. doi: 10.14336/AD.2024.1080.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ge Y, Zhou S, Li Y, et al. Estrogen prevents articular cartilage destruction in a mouse model of AMPK deficiency via ERK-mTOR pathway. Ann Transl Med. 2019;7(14):336. doi: 10.21037/atm.2019.06.77.</mixed-citation><mixed-citation xml:lang="en">Ge Y, Zhou S, Li Y, et al. Estrogen prevents articular cartilage destruction in a mouse model of AMPK deficiency via ERK-mTOR pathway. Ann Transl Med. 2019;7(14):336. doi: 10.21037/atm.2019.06.77.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11(5):241. doi: 10.1186/ar2791.</mixed-citation><mixed-citation xml:lang="en">Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11(5):241. doi: 10.1186/ar2791.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen C, Coudeyre E, Boutron I, et al. Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL). PLoS Med. 2024;21(8):e1004440. doi: 10.1371/journal.pmed.1004440.</mixed-citation><mixed-citation xml:lang="en">Nguyen C, Coudeyre E, Boutron I, et al. Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL). PLoS Med. 2024;21(8):e1004440. doi: 10.1371/journal.pmed.1004440.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Vo NX, Le NNH, Chu TDP, et al. Effectiveness and Safety of Glucosamine in Osteoarthritis: A Systematic Review. Pharmacy (Basel). 2023;11(4):117. doi: 10.3390/pharmacy11040117</mixed-citation><mixed-citation xml:lang="en">Vo NX, Le NNH, Chu TDP, et al. Effectiveness and Safety of Glucosamine in Osteoarthritis: A Systematic Review. Pharmacy (Basel). 2023;11(4):117. doi: 10.3390/pharmacy11040117</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Honvo G, Bruyère O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019;36(5):1085-1099. doi: 10.1007/s12325019-00921-w.</mixed-citation><mixed-citation xml:lang="en">Honvo G, Bruyère O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019;36(5):1085-1099. doi: 10.1007/s12325019-00921-w.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Manocchio N, Pirri C, Ljoka C, et al. Long-Term Efficacy of Carboxymethyl-Chitosan in Advanced Knee Osteoarthritis: A Twelve-Month Follow-Up Study on Non-Responders to Hyaluronic Acid. Biomedicines. 2025;13(2):270. doi: 10.3390/biomedicines13020270.</mixed-citation><mixed-citation xml:lang="en">Manocchio N, Pirri C, Ljoka C, et al. Long-Term Efficacy of Carboxymethyl-Chitosan in Advanced Knee Osteoarthritis: A Twelve-Month Follow-Up Study on Non-Responders to Hyaluronic Acid. Biomedicines. 2025;13(2):270. doi: 10.3390/biomedicines13020270.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-284. doi: 10.1016/j.cell.2009.09.028.</mixed-citation><mixed-citation xml:lang="en">Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-284. doi: 10.1016/j.cell.2009.09.028.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Clegg Daniel O., Reda Domenic J., Harris Crystal L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. doi: 10.1056/NEJMoa052771.</mixed-citation><mixed-citation xml:lang="en">Clegg Daniel O., Reda Domenic J., Harris Crystal L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. doi: 10.1056/NEJMoa052771.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Emans PJ, Skaliczki G, Haverkamp D, et al. First-in-human Study to Evaluate a Single Injection of KiOmedine®CM-Chitosan for Treating Symptomatic Knee Osteoarthritis. Open Rheumatol J. 2022;16. doi: 10.2174/18743129-v16-e2206100.</mixed-citation><mixed-citation xml:lang="en">Emans PJ, Skaliczki G, Haverkamp D, et al. First-in-human Study to Evaluate a Single Injection of KiOmedine®CM-Chitosan for Treating Symptomatic Knee Osteoarthritis. Open Rheumatol J. 2022;16. doi: 10.2174/18743129-v16-e2206100.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Marouf BH, Hussain SA, Ali ZS, Ahmmad RS. Clinical efficacy of resveratrol as an adjuvant with meloxican in the treatment of knee osteoarthritis patients: A double-blind, randomised, placebo-controlled trial. Braz J Pharm Sci. 2018;54(4):e17773. doi: 10.1590/s2175-97902018000417773.</mixed-citation><mixed-citation xml:lang="en">Marouf BH, Hussain SA, Ali ZS, Ahmmad RS. Clinical efficacy of resveratrol as an adjuvant with meloxican in the treatment of knee osteoarthritis patients: A double-blind, randomised, placebo-controlled trial. Braz J Pharm Sci. 2018;54(4):e17773. doi: 10.1590/s2175-97902018000417773.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63(8):901-907. doi:10.1136/ard.2003.018531.</mixed-citation><mixed-citation xml:lang="en">Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63(8):901-907. doi:10.1136/ard.2003.018531.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
